Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
RGD PET/CT in Lung or Head and Neck Cancer
NCT02325349Phase 2Terminated
- Sponsor
- Assistance publique - Hôpitaux de Paris
- Start
- Mar 2015
- Primary completion
- Sep 2018
- Modality
- Peptides, Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of 18F-FPPRGD2 and gallium Ga 68-RGD in head and neck carcinoma (HNC) and non-small cell lung carcinoma (NSCLC), sponsored by Assistance publique - Hôpitaux de Paris. Primary endpoint: Response to treatment based on RECIST criterion at 21 days. Started Mar 2015; status: terminated.
02
Drugs
18F-FPPRGD2gallium Ga 68-RGD
03
Conditions
head and neck carcinoma (HNC)non-small cell lung carcinoma (NSCLC)
Beyond the preview
Go deeper on NCT02325349.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02325349.